RxDoctor Payments DataLook up a doctor →

Qasim Cheema, MD

Interventional Cardiology · Jackson, MSNPI 1376750372

Payments from drug & device makers

$11,966in general payments, 2019–2025

Across 581 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$4K
  • Abbott$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Medtronic$756
  • Boston Scientific$623
  • Novartis$486
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$11,956100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,966 in reported general payments places this provider in the 55th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$64,884
Medicare patients
259
Services billed
734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban200$157,146
BrilintaTicagrelor136$83,365
EntrestoSacubitril/Valsartan91$78,036
XareltoRivaroxaban14$12,869
Ranolazine ErRanolazine27$3,059
Nitroglycerin215$2,229
Atorvastatin Calcium313$1,997
ClopidogrelClopidogrel Bisulfate185$1,524
Carvedilol279$1,479
Metoprolol Succinate129$1,407
Pravastatin Sodium113$1,404
Isosorbide Mononitrate ErIsosorbide Mononitrate166$1,400
Metoprolol Tartrate238$1,326
Amlodipine Besylate255$1,181
Hydralazine Hcl110$1,157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$157,146200 claims
AstraZenecaBrilinta$152$83,365136 claims
NovartisEntresto$486$78,03691 claims
Johnson & JohnsonXarelto$328$12,86914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →